Key result
Cardiac microcurrent therapy shows preclinical potential to improve LVEF and functional capacity in HF.
Why the study?
Heart failure is an often irreversible end stage of cardiovascular disease for which current therapies are largely palliative rather than restorative, prompting exploration of cardiac microcurrent therapy.
Does cardiac microcurrent therapy improve cardiac repair and function in heart failure with reduced ejection fraction?
Does cardiac microcurrent therapy improve cardiac repair and function in heart failure with reduced ejection fraction?
Cardiac microcurrent therapy shows preliminary mechanistic and clinical promise for cardiac repair in HFrEF, highlighting the need for adequately powered sham-controlled trials.
Answers are grounded in this paper and cite their sources.
Microcurrent therapy may offer a restorative option in nonischemic HFrEF; first RCT evidence extends bioelectronic approaches to remodeling.
Cardiovascular disease remains a major cause of morbidity and mortality, with heart failure representing the common and often irreversible end stage, for which current therapies are largely palliative rather than restorative. Cardiac microcurrent therapy delivers a low-intensity, nondepolarizing direct current across the myocardium and has been proposed to modulate fibrosis, inflammation, and remodeling in heart failure with reduced ejection fraction. In Cardiac Microcurrent I (New York Heart Association III nonischemic heart failure with reduced ejection fraction), left ventricular ejection fraction increased by 12.6% at 6 months, 6-minute walk distance improved by 191 m, and 8 of 10 patients improved to New York Heart Association I within 2 weeks. In the randomized Cardiac Microcurrent II trial, patients showed further improvements, including a 5.1% increase in left ventricular ejection fraction, a reduction in New York Heart Association class (up to 69%), and a 38 m increase in 6-minute walk distance. However, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels did not show a consistent corresponding reduction. In vitro, microcurrent altered the myofibroblast phenotype and reduced the expression of transforming growth factor-β1, collagen, α-smooth muscle actin, and fibronectin. Transcriptomics revealed downregulation of inflammatory and immune pathways, while cardiomyocytes from spontaneously hypertensive rats exhibited enhanced survival and stress resistance. This review combines early clinical observations and preclinical findings to examine potential mechanisms of action and bioelectrical effects of cardiac microcurrent therapy. Given the limited clinical evidence and largely in vitro nature of the data, the current mechanistic findings should be considered preliminary. We highlight key knowledge gaps and propose future studies to define molecular mechanisms, discover biomarkers, analyze key signaling pathways, and evaluate clinical outcomes in adequately powered, sham-controlled trials, which could further validate this therapeutic approach.
No takes yet. Share an insight, caveat, or question.
Rame et al. (2026) conducted a review in heart failure with reduced ejection fraction. Cardiac microcurrent therapy was evaluated. Cardiac microcurrent therapy shows potential to improve left ventricular ejection fraction and functional capacity in heart failure, though current evidence is limited and largely preclinical.
Synapse has enriched 10 related papers. Consider them for comparative context: